They will slowly disappear with time
In rat studies, BPC-157 demonstrated healing effects in various colitis models, including cysteamine-induced colitis, improved intestinal anastomosis healing, and promoted closure of gastrointestinal fistulascomplications relevant to Crohn's disease.[4][5][3] The proposed mechanisms include interaction with the nitric oxide system, angiogenic effects, endothelium protection, and modulation of growth factor expression.[1][6] Critical limitations include the lack of published results from controlled human trials, absence of FDA approval, and concerns about products being sold online without regulatory oversight.[2] The peptide was temporarily banned by the World Anti-Doping Agency in 2022, though it is not currently listed as banned.[2] Given these limitations, BPC-157 cannot be recommended as standard therapy for ulcerative colitis or Crohn's disease based on current evidence
Sleep loss and cytokines levels in an experimental model of psoriasis
If grocers arent ready when the GLP-1 trend hits their market and their customers go elsewhere for an experience that better suits their new lifestyle, not all will return, and not all will bring back their full baskets even if they do
meta-analysis: OR = 0.55, 95% CI [0.320.93])